Climb Bio (CLYM) to Release Earnings on Tuesday

Climb Bio (NASDAQ:CLYM) is anticipated to release its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Climb Bio to post earnings of ($0.22) per share for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.06. On average, analysts expect Climb Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Climb Bio Price Performance

Shares of Climb Bio stock traded up $0.63 during trading hours on Tuesday, hitting $12.44. The company had a trading volume of 231,847 shares, compared to its average volume of 904,983. The company’s 50-day moving average is $12.22 and its two-hundred day moving average is $9.07. The company has a market cap of $712.37 million, a P/E ratio of -15.95 and a beta of 0.08. Climb Bio has a twelve month low of $1.54 and a twelve month high of $14.41.

Hedge Funds Weigh In On Climb Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hsbc Holdings PLC grew its holdings in Climb Bio by 107.2% during the fourth quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock worth $99,000 after acquiring an additional 12,800 shares during the period. Virtu Financial LLC purchased a new stake in shares of Climb Bio during the 4th quarter worth $43,000. XTX Topco Ltd grew its stake in shares of Climb Bio by 19.4% during the 4th quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock worth $139,000 after purchasing an additional 5,668 shares during the period. Squadron Capital Management LLC purchased a new position in shares of Climb Bio in the 4th quarter valued at about $400,000. Finally, Sphera Funds Management LTD. increased its holdings in shares of Climb Bio by 114.4% in the 4th quarter. Sphera Funds Management LTD. now owns 932,247 shares of the company’s stock valued at $3,729,000 after purchasing an additional 497,410 shares in the last quarter. Institutional investors and hedge funds own 69.76% of the company’s stock.

Wall Street Analyst Weigh In

CLYM has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Climb Bio in a report on Wednesday, June 24th. Oppenheimer raised their price target on Climb Bio from $10.00 to $18.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 21st. Wedbush raised their price target on Climb Bio from $17.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, July 27th. Robert W. Baird set a $21.00 price objective on Climb Bio in a research note on Wednesday, May 6th. Finally, Chardan Capital began coverage on Climb Bio in a report on Tuesday, May 5th. They issued a “buy” rating and a $22.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $22.08.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.